Medtronic ((MDT)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD) by Medtronic aims to assess the recurrence of unstable ventricular tachycardia (VT) in patients who receive ICD implantation with substrate ablation versus those who only receive ICD implantation. The study’s primary goal is to improve the quality of life for patients, rather than reducing mortality rates.
The interventions tested include ICD Therapy plus VT-Ablation, which combines ICD therapy with catheter ablation for substrate modification, and ICD Therapy only, which involves the use of an ICD device to treat unstable VT.
This interventional study follows a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. The study is categorized as Phase 4, indicating it is conducted after FDA approval to gather additional information on the treatment’s effectiveness.
The study began in May 2002, with its primary completion date not specified. The last update was submitted on June 30, 2025, indicating the study’s ongoing status and recent developments.
The completion of this study could have significant implications for Medtronic’s market performance, potentially boosting investor confidence and stock value due to advancements in cardiac treatment technologies. Competitors in the cardiac device industry may also feel pressure to innovate in response to these findings.
The study is ongoing, with further details available on the ClinicalTrials portal.